SOSEI HEPTARES
LIVE

Serial Number

79288175

Owner

Sosei Group Corporation

Attorney

Rebecca Liebowitz

Filing Date

Apr 9, 2020

Add to watchlist:

No watchlists yet
View on USPTO

SOSEI HEPTARES Trademark

Serial Number: 79288175 • Registration: 6829584

SOSEI HEPTARES is a trademark filed by Sosei Group Corporation on April 9, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Sosei Group Corporation (13 trademarks)

2-4 Kojimachi, Chiyoda-ku

Entity Type: 98

Nxera Pharma Co., Ltd (7 trademarks)

9-7-2 Akasaka Minato-ku

Entity Type: 98

Trademark Details

Filing Date

April 9, 2020

Registration Date

August 30, 2022

Published for Opposition

June 14, 2022

Goods & Services

Bio-technology, pharmaceutical and scientific testing, research and development; biological research services; research and development services in the pharmaceutical and biopharmaceutical fields;, research and development services in the pharmaceutical and biopharmaceutical fields, namely, in the field of technologies related to proteins and G-protein-coupled receptors; research services in biology and chemistry fields; pharmaceutical research services in chemical and biological drug discovery and development; scientific and pharmaceutical research and development services for identifying lead chemical compounds; scientific analysis and research services in medicinal and synthetic chemistry; research and development services in the creation of libraries or collections of biologicals, chemicals and compounds; pharmaceutical research and development in the nature of research, creation, development and provision of chemical and biological drug targets for non-medical scientific screening purposes; technical diagnostic testing services, namely, scientific and pharmaceutical research and development; scientific research, analysis and examination for identification of compounds through automated screening processes, being scientific and pharmaceutical research and development; research and development services in chemical and biological pharmaceutical development; provision of information, advisory services and consultancy relating to the aforesaid services

chemical products and proteins for manufacturing chemical and biological pharmaceutical products; chemical products and proteins for the scientific research of chemical and biological pharmaceutical products; chemical products and proteins for diagnostic use, except medical or veterinary uses, namely, diagnostic preparations for scientific use; proteins and specifically proteins in the nature of G-protein-coupled receptors for manufacturing pharmaceutical products; proteins and specifically proteins in the nature of G-protein-coupled receptors, for the scientific research of pharmaceutical products; chemicals and proteins for chemical and biological drug discovery, lead identification and diagnostics, namely, chemical and biological preparations for use in scientific purposes; proteins and G-protein-coupled receptors for drug discovery purpose, namely, proteins and biological preparations for use in scientific research; chemicals preparations and biologicals preparations for scientific research purposes, being proteins, transmembrane proteins and G proteins, G-protein-coupled receptors, and fragments thereof being sequences of amino acids, for chemical and biological drug discovery, lead identification and diagnostics; proteins, including transmembrane proteins and G-proteins, G-protein-coupled receptors, and fragments thereof being sequences of amino acids, all for use in scientific pharmaceutical research and scientific pharmaceutical research in the nature of drug discovery purposes

Biological products for medical use in chemical and biological drug discovery, lead identification and diagnostics, namely, diagnostic preparations for medical use and pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; biological products for therapeutic purposes, namely, pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; proteins for medical use in chemical and biological drug discovery, lead identification and diagnostics, namely, diagnostic preparations for medical use and pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; medicines, namely, diagnostic preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; cleaning agent for medical use, namely, medical cleansers for skin wounds; biological formulation for medical use in developing chemical and biological pharmaceutical products, namely, pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; biological formulation for medical use in identifying lead chemical and biological products, namely, diagnostic preparations for medical use and pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; biological formulation for medical diagnostic use, namely, diagnostic preparations for medical use; biological formulation for therapeutic use, namely, pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; proteins and G-protein-coupled receptors for medical use in drug discovery; biologicals and small chemical entities, including proteins, G-protein-coupled receptors, transmembrane proteins, G-proteins, antibodies and peptides for therapeutic purposes, namely, diagnostic preparations for medical use; proteins, G-protein-coupled receptors, transmembrane proteins, G-proteins, antibodies and peptides for use in medical diagnostics, namely, diagnostic preparations for medical use and pharmaceutical preparations for the treatment of conditions and diseases of the central nervous system, metabolic system, inflammatory disorders, immune system, cancer, cardiovascular system, reproductive system, respiratory system, ocular system, for use in dermatology, gastrointestinal system, pain relief and neuromuscular system; medical oiled paper; drug delivery agents in the form of edible pharmaceutical wafers for wrapping powdered pharmaceuticals; gauze for dressings; specialized capsules for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; eye patches for medical purposes, ear bandages; menstrual bands being sanitary pads; menstrual tampons; menstrual napkins, namely, menstrual symptom treatment preparations; menstrual underwear, namely, panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; collodion for pharmaceutical purposes; cotton swabs for medical purposes; breast-nursing pads

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Feb 19, 2026 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Feb 19, 2026 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Feb 19, 2026 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 14, 2024 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 27, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 7, 2022 FICS
FINAL DISPOSITION PROCESSED
Dec 7, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 30, 2022 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Nov 4, 2022 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 30, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 30, 2022 R.PR
NOTIFICATION PROCESSED BY IB
Jul 5, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 14, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 14, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 8, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 8, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 25, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2022 CRFA
ASSIGNED TO LIE
May 5, 2022 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 30, 2022 ERSI
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 14, 2022 RCSC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Dec 19, 2021 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 1, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 1, 2021 OPNR
CORRESPONDENCE E-MAILED
Sep 9, 2021 GRML
SUSPENSION LETTER WRITTEN
Sep 9, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 9, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 9, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 9, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 9, 2021 GNFN
FINAL REFUSAL E-MAILED
Mar 9, 2021 GNFR
FINAL REFUSAL WRITTEN
Mar 9, 2021 CNFR
EXAMINER'S AMENDMENT ENTERED
Mar 5, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 5, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 5, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 5, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 4, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 4, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 4, 2021 TROA
REFUSAL PROCESSED BY IB
Aug 30, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 11, 2020 RFCS
REFUSAL PROCESSED BY MPU
Aug 11, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 3, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jul 2, 2020 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jun 30, 2020 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 30, 2020 RFCR
APPLICATION FILING RECEIPT MAILED
Jun 30, 2020 MAFR
NON-FINAL ACTION WRITTEN
Jun 29, 2020 CNRT
ASSIGNED TO EXAMINER
Jun 26, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 26, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 25, 2020 REPR